ClinicalTrials.gg
RecruitingNCT06948448Updated Jul 16, 2026

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

A Phase 2 interventional study of ONO-4578 and Opdivo® in Colorectal Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 39 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
647th of 1,932
144 · median 64
Started
2025
with 142 others
Phase 2
510 of 2,339
65 open now
Primary completion
2028-02
later than 398 of 628 live
Registered
2,142nd of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 647th largest by planned enrollment of the 1,932 interventional ones that give a count, is one of 143 that started in 2025, is one of 510 in phase 2, reaches primary completion later than 398 of the 628 other live ones, and was the 2,142nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

413 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.

Read the detailed description

Potential participants will be consented and screened for study eligibility. Eligible participants will be randomized in a 1:1:1 ratio to one of the three study intervention arms. Study intervention will be administered in 28-day treatment cycles and continued until disease progression, intolerable toxicity, Investigator decision or withdrawal of consent by the participant, or termination of the study by the Sponsor.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed advanced (locally advanced or ) colorectal cancer not amenable to curative resection
  • Performance Status of 0-1
  • No prior systemic treatment for advanced local or mCRC
  • Participants whose tumor is positive for expression as determined at a central laboratory

Exclusion criteria

Exclusion Criteria:

  • Participants with high microsatellite instability (MSI-High), or mismatch repair deficient (dMMR) tumor
  • Participants with BRAF V600E mutation
  • Unable to swallow tablets.
  • Participants with complication or history of interstitial lung disease, pneumonitis or pulmonary fibrosis
  • Participants with an active, known or suspected disease.
  • Prior treatment with an , anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Arm A ONO-4578 dose 1 + Opdivo® + SOC (mFOLFOX6 + bevacizumab)

    Drug: ONO-4578 · Drug: Opdivo® · Drug: Oxaliplatin · Drug: 5-Fluorouracil · Drug: Bevacizumab · Drug: Leucovorin

  • Experimental
    Arm B ONO-4578 dose 2 + Opdivo® + SOC (mFOLFOX6 + bevacizumab)

    Drug: ONO-4578 · Drug: Opdivo® · Drug: Oxaliplatin · Drug: 5-Fluorouracil · Drug: Bevacizumab · Drug: Leucovorin

  • Active comparator
    Arm C SOC (mFOLFOX6+bevacizumab)

    Drug: Oxaliplatin · Drug: 5-Fluorouracil · Drug: Bevacizumab · Drug: Leucovorin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) per Blinded Independent Central Review (BICR)

    ORR (assessed by BICR per RECIST v1.1) is defined as the proportion of participants with a BOR of confirmed CR or PR. The ORR will be estimated as the number of participants achieving BOR of CR or PR assessed by BICR per RECIST v1.1 divided by the total number of participants.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  2. Number of participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study patient, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: From first dose to 28 days post last dose

  3. Number of participants with Serious Adverse Events (SAEs)

    SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in significant disability/incapacity.

    Time frame: From first dose to 28 days post last dose

Secondary outcomes

  1. Overall Response Rate (ORR) per Investigator assessment

    ORR (assessed by site Investigator per RECIST v1.1) is defined as the proportion of participants with a BOR of confirmed CR or PR. The ORR will be estimated as the number of participants achieving BOR of CR or PR assessed by site Investigator per RECIST v1.1 divided by the total number of participants.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  2. Overall Survival (OS)

    OS is defined as the time between the date of randomization and the date of death due to any cause.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  3. Progression-Free Survival (PFS) by BICR

    PFS by BICR is defined as the time from date of randomization to the date of the first documented progressive disease (PD) as determined by BICR per RECIST version 1.1, or the date of death due to any cause, whichever occurs first.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  4. Progression-Free Survival (PFS) by Investigator assessment

    PFS by Investigator assessment is defined as the time from date of randomization to the date of the first documented progressive disease (PD) as determined by site Investigator per RECIST version 1.1, or the date of death due to any cause, whichever occurs first.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  5. Best overall response (BOR) by BICR

    BOR is defined as the best response designation, recorded between the start of the study intervention and the date of the initial objectively documented PD per RECIST v1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  6. Best overall response (BOR) by Investigator assessment

    BOR is defined as the best response designation, recorded between the start of the study intervention and the date of the initial objectively documented PD per RECIST v1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  7. Duration of response (DOR) by BICR

    DOR is defined as the time between the date of first confirmed CR or PR to the date of the first documented PD per RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  8. Duration of response (DOR) by Investigator assessment

    DOR is defined as the time between the date of first confirmed CR or PR to the date of the first documented PD per RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  9. Disease Control Rate (DCR) by BICR

    DCR is defined as the percentage of participants whose BOR is determined to be CR, PR, or stable disease (SD).

    Time frame: From randomization to the end of treatment (Up to 39 months)

  10. Disease Control Rate (DCR) by Investigator assessment

    DCR is defined as the percentage of participants whose BOR is determined to be CR, PR, or stable disease (SD).

    Time frame: From randomization to the end of treatment (Up to 39 months)

  11. Time to Response (TTR) by BICR

    TTR is defined as the time from the date of randomization to the date of first confirmed CR or PR.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  12. Time to Response (TTR) by Investigator assessment

    TTR is defined as the time from the date of randomization to the date of first confirmed CR or PR.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  13. Maximum percent change in the sum of the diameters of the target lesions by BICR

    In participants who have target lesions at baseline and at least 1 post-baseline imaging evaluation, the maximum percent change in the sum of diameters of target lesions is the percent change at the point of the minimum sum of diameters of the target lesions.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  14. Maximum percent change in the sum of the diameters of the target lesions by Investigator assessment

    In participants who have target lesions at baseline and at least 1 post-baseline imaging evaluation, the maximum percent change in the sum of diameters of target lesions is the percent change at the point of the minimum sum of diameters of the target lesions.

    Time frame: From randomization to the end of treatment (Up to 39 months)

  15. Progression-Free Survival of second line therapy (PFS2) by Investigator assessment

    PFS2 is defined as the time from date of randomization to the date of an overall response of PD after subsequent anti-cancer therapy, initiating date of a second subsequent anti-cancer therapy, or date of death from any cause, whichever occurs first.

    Time frame: From randomization to the end of treatment (Up to 39 months)

07

Study locations

39 of 39 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2028, 26 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 26 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2025
First posted
Apr 29, 2025
StartActual
Nov 18, 2025
Primary completionEst.
Feb 15, 2028
CompletionEst.
Oct 1, 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06948448
Responsible party
Sponsor
First posted
Apr 29, 2025
Start date
Nov 18, 2025
Primary completion
Feb 15, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Jul 16, 2026

Study contacts

North America Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+18665877745(Toll-Free)
International Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+17162141777(Standard)
Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMS-986310

Start the discussion